Milestone Pharmaceuticals Inc — Financial Statements (NASDAQ:MIST) | MetaTrader

Open full chart

Haberler

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’un PSVT tedavisi CARDAMYST artık ABD eczanelerinde satışta

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Avrupa düzenleyicileri PSVT için etripamil burun spreyi başvurusunu kabul etti

Aptar’ın burun spreyi sistemi yeni onaylanan PSVT tedavisini sunacak

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

TD Cowen, FDA onayı sonrası Milestone Pharmaceuticals hisse senedi notunu Al’a yükseltti

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15

Milestone stock soars after FDA approves first self-administered PSVT spray